Compare Gilead Sciences, Inc. (GILD) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Teradyne, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.55 (market cap $163.51B), while Teradyne, Inc. trades at $323.15 (market cap $53.56B). The key difference: Gilead Sciences, Inc. is far larger — about 3.1× Teradyne, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TER | |
|---|---|---|
Market Cap | $163.51B | $53.56B |
Sector | Health | Technology |
52-Week High | $155.80 | $483.84 |
52-Week Low | $108.22 | $90.15 |
Enterprise Value | $178.05B | $53.39B |
Dividend Yield | 2.49% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Teradyne (TER) trades at $353.23, up 3.55% today, with a bearish technical signal but strong fundamental performance. Recent earnings beats and a 64.52% analyst buy rating support optimism, though high valuation ratios like a P/E of 63.47 and negative net cash flow trends pose concerns. The stock is positioned near its pivot point of $354, with support at $347 and resistance at $360.
Outlook: Growth driven by AI and semiconductor testing demand offers upside to the $453.60 consensus target, but elevated valuations and cash flow challenges present risks. Investors should weigh robust profitability against potential volatility from market sentiment and execution hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
